Aldebaran Financial Inc. purchased a new position in shares of Albemarle Co. (NYSE:ALB) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 20,153 shares of the specialty chemicals company’s stock, valued at approximately $2,747,000. Albemarle comprises approximately 1.9% of Aldebaran Financial Inc.’s portfolio, making the stock its 17th biggest holding.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Baillie Gifford & Co. grew its position in Albemarle by 100.8% during the 2nd quarter. Baillie Gifford & Co. now owns 184,555 shares of the specialty chemicals company’s stock worth $19,478,000 after acquiring an additional 92,650 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Albemarle in the 2nd quarter worth approximately $439,000. Lord Abbett & CO. LLC bought a new stake in shares of Albemarle in the 2nd quarter worth approximately $11,681,000. Sumitomo Life Insurance Co. bought a new stake in shares of Albemarle in the 3rd quarter worth approximately $1,703,000. Finally, Vanguard Group Inc. grew its position in shares of Albemarle by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 12,501,329 shares of the specialty chemicals company’s stock worth $1,319,389,000 after buying an additional 213,530 shares during the last quarter. Institutional investors and hedge funds own 88.10% of the company’s stock.
A number of brokerages have recently weighed in on ALB. UBS lifted their price objective on Albemarle from $123.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, November 9th. Jefferies Group reiterated a “buy” rating on shares of Albemarle in a research report on Tuesday, October 24th. BMO Capital Markets began coverage on Albemarle in a research report on Tuesday, October 24th. They issued an “outperform” rating and a $160.00 price objective on the stock. Royal Bank of Canada reiterated a “buy” rating and issued a $136.00 price objective on shares of Albemarle in a research report on Wednesday, September 20th. Finally, Goldman Sachs Group lowered Albemarle from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $139.66 to $142.00 in a research report on Friday, October 6th. Ten investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $128.45.
Albemarle Co. (NYSE ALB) opened at $130.10 on Thursday. The company has a market capitalization of $14,404.21, a P/E ratio of 32.27, a PEG ratio of 1.97 and a beta of 1.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.11 and a quick ratio of 1.56. Albemarle Co. has a one year low of $85.60 and a one year high of $144.99.
Albemarle (NYSE:ALB) last released its earnings results on Wednesday, November 8th. The specialty chemicals company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $1.07 by $0.01. The company had revenue of $755.00 million during the quarter, compared to analysts’ expectations of $732.19 million. Albemarle had a return on equity of 11.61% and a net margin of 30.07%. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.91 EPS. analysts expect that Albemarle Co. will post 4.46 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 2nd. Shareholders of record on Friday, December 15th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date is Thursday, December 14th. Albemarle’s payout ratio is 16.56%.
COPYRIGHT VIOLATION WARNING: This piece was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://ledgergazette.com/2017/12/14/aldebaran-financial-inc-purchases-new-stake-in-albemarle-co-alb.html.
Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.